ResultsIQ › Latest results › Gujarat Themis Biosyn Limited
Gujarat Themis Biosyn Limited Q2 FY27 results deck summary
NSE: GUJTHEM · BSE: 506879
Results deck of 15 Nov 2026, summarised by AI from the filing.
Standalone Q2 FY27 revenue rose 12.1% to ₹47.5 cr, but EBITDA fell to ₹17.7 cr on new-facility commissioning and acquisition financing costs.
Key takeaways
- Q2 margin fall Standalone Q2 FY27 revenue rose to ₹47.5 cr (Q2 FY26: ₹42.3 cr, +12.1%), but EBITDA fell to ₹17.7 cr and PAT to ₹8.5 cr.
- Guidance Management expects new-capacity revenue contribution and operating benefits to become increasingly visible from Q4 FY27 onwards.
- Growth driver Growth came from volume momentum and a favourable product mix shift towards APIs.
- Margin risk Commissioning of the new fermentation facility and acquisition financing costs pulled near-term profitability down.
Gujarat Themis Biosyn Limited Q2 FY27 results
As filed: Revenue ₹47.5 cr (+13% year on year), EBITDA ₹17.7 cr (−16% year on year), PAT ₹8.5 cr (−40% year on year), EBITDA margin 37.3% (−1,000 bps).
The Q2 FY27 score, against the company's own trend, is for premium members.
Earlier results and the share price after them
- Q1 FY27: Revenue ₹43.8 cr (+22% year on year), EBITDA ₹20.8 cr (+49% year on year), PAT ₹11.1 cr (+23% year on year), EBITDA margin 47.5% (+861 bps). Score 79 of 100, Above trend. EBITDA margin rose 861 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: +13.7% in 28 days (Nifty 500: −2.0%).
- Q4 FY26: Revenue ₹44.2 cr (+16% year on year), EBITDA ₹19.4 cr (+21% year on year), PAT ₹10.9 cr (−9% year on year), EBITDA margin 43.8% (+169 bps). Score 55 of 100, In line with trend. EBITDA margin rose 169 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 13% from last quarter. Share price after the results: +8.8% in 30 days (Nifty 500: +2.1%).
- Q3 FY26: Revenue ₹43.4 cr, EBITDA ₹21.3 cr, PAT ₹12.5 cr, EBITDA margin 49.1%. Not scored. No result for the same quarter last year. Share price after the results: −9.3% in 29 days (Nifty 500: −4.0%).
- Q2 FY26: Revenue ₹42.0 cr, EBITDA ₹21.0 cr, PAT ₹14.0 cr, EBITDA margin 50.0%. Not scored. No result for the same quarter last year. Share price after the results: −14.8% in 30 days (Nifty 500: −0.5%).
- Q1 FY26: Revenue ₹36.0 cr, EBITDA ₹14.0 cr, PAT ₹9.0 cr, EBITDA margin 38.9%. Not scored. No result for the same quarter last year. Share price after the results: −3.2% in 28 days (Nifty 500: −2.0%).
- Q4 FY25: Revenue ₹38.0 cr, EBITDA ₹16.0 cr, PAT ₹12.0 cr, EBITDA margin 42.1%. Not scored. No result for the same quarter last year. Share price after the results: −3.3% in 30 days (Nifty 500: +0.8%).
Past price moves after results do not indicate future moves. Not a recommendation.
Gujarat Themis Biosyn Limited earnings call, investor presentation and press release summaries
- Q2 FY27: Results deck (15 Nov 2026)
- Q1 FY27: Earnings call (10 Aug 2026), Results deck (7 Aug 2026)
- Q4 FY26: Results deck (25 May 2026)
- Q3 FY26: Results deck (5 Feb 2026)
- Q2 FY26: Results deck (10 Nov 2025)
- Q1 FY26: Results deck (1 Aug 2025)
- Q4 FY25: Results deck (20 May 2025)
- Other events: Strategy deck (29 Jun 2026), Strategy deck (22 May 2026), Strategy deck (23 Apr 2026)
Figures from the company's filings with NSE and BSE. Not investment advice.